Drug Profile
Research programme: CRM197 fusion constructs - Vyera Pharmaceuticals
Alternative Names: Cross reacting material 197 fusion constructs - Vyera; Diphtheria toxin fusion constructs - Vyera PharmaceuticalsLatest Information Update: 28 Dec 2019
Price :
$50
*
At a glance
- Originator Turing Pharmaceuticals
- Developer The Hospital for Sick Children; Vyera Pharmaceuticals
- Class Recombinant fusion proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for research development in Unspecified in USA
- 01 Sep 2017 Turing Pharmaceuticals is now called Vyera Pharmaceuticals
- 12 Nov 2015 Early research in Undefined indication in USA (unspecified route)